ライフサイエンスコーパス: biological agent

1 t could be wrought by a terrorist's use of a biological agent.

2 actuality it is a combination of solvent and biological agent.

3 2.40%) and 19.39% had previous exposure to a biological agent.

4 extremely enrich the design of sophisticated biological agents.

5 e enough to be compatible with sophisticated biological agents.

6 tifying and managing casualties from various biological agents.

7 ombining anti-VEGF therapy with cytotoxic or biological agents.

8 n ideal target for site-specific delivery of biological agents.

9 orally active small molecule alternatives to biological agents.

10 es limits the therapeutic potential of these biological agents.

11 hn's disease, there are few clinical data on biological agents.

12 are not appreciably degraded by a variety of biological agents.

13 ession of these changes could be produced by biological agents.

14 le to misuse and the production of dangerous biological agents.

15 group without detectable similarity to known biological agents.

16 understanding of learning in artificial and biological agents.

17 CD, regardless of previous exposure to other biological agents.

18 trating, processing and sensing chemical and biological agents.

19 ologies and may complement current anti-VEGF biological agents.

20 tribution against a robust database of known biological agents.

21 ling to consider as vehicles for delivery of biological agents.

22 signaling pathways with small molecules and biological agents.

23 ions and high costs restrict prescription of biological agents.

24 d supplementation, herbal products and other biological agents, acupuncture, massage, exercise, and p

25 ated as low risk of bias and showed that all biological agents (adalimumab, golimumab, infliximab, an

26 Biological agents adapt behavior to support the survival

27 re cystectomy and consolidation therapy with biological agents after first-line therapy provide a fra

28 ains could be used as promising eco-friendly biological agents against C. capitata.

29 In the past few years, new biological agents against complement, the FcRn receptor,

30 The development of neutralising biological agents against TNF-alpha has allowed us to te

31 In parallel with the development of several 'biological' agents, alternative therapeutic options have

32 inflammasome or the IL-1 receptor-targeting biological agent anakinra.

33 Dependent on the biological agent and contaminated food, such an outbreak

34 d that human stool should be classified as a biological agent and its use should be regulated to ensu

35 of adverse reactions associated with use of biological agents and could be used to better understand

36 New therapeutic approaches, such as biological agents and mycophenolate mofetil, will also b

37 Disease-modifying biological agents and other drug regimens have substanti

38 of adverse events was not different between biological agents and placebo.

39 he association between the administration of biological agents and psychopathology needs to be furthe

40 Exposure to multiple biological agents and risk of reporting eczema, allergy

41 nt as well as possible new insulin-releasing biological agents and small-molecule inhibitors of gluca

42 New biological agents and somatostatin-tagged radionuclides

43 more human-like could profit from a study of biological agents and their evolution.

44 nitor the location and transfer of hazardous biological agents and to insure that any use of such age

45 omise include intravenous immunoglobulin and biological agents and trials of the newest treatments ar

46 r involvement of the liver, planned use of a biological agent, and investigational centre.

47 C or CD treated to endoscopic remission with biological agents, and C: healthy normal controls.

48 -2 in vivo for use in combination with other biological agents, and for studies of its antitumor acti

49 TNFs, IBD patients treated to remission with biological agents, and healthy normal controls.

50 al development stages for genetic medicines, biological agents, and immunotherapies.

51 es have yet to be undertaken for these novel biological agents, and it is unclear whether any of thes

52 gulations in humane animal care, safe use of biological agents, and medical care delivery.

53 options have expanded with the advent of the biological agents, and these may yet improve outcomes, p

54 o selectively engineer the NP, to colocalize biological agents, and to enhance the stability of those

55 particularly steroids, immunomodulators, and biological agents; and a high risk of recurrence.

56 Biological agents are effective treatments for UC, but h

57 Biological agents are emerging treatment options for the

58 vel evidence for the therapeutic efficacy of biological agents are redefining diagnosis and care.

59 In the West, biological agents are the fastest-growing segment of the

60 Biological agents are the most complex systems humans ha

61 As newer biological agents are translated from the lab to the bed

62 Biological agents are used when arthritis is uncontrolle

63 Biological agents are widely used across medicine, inclu

64 Treatment regimens for AMD, especially with biological agents, are complicated due to anatomical and

65 In particular, the use of biological agents as radiosensitizers has led to the inv

66 The modern development of biological agents as weapons has paralleled advances in

67 , or a second anti-TNF drug as a second-line biological agent at 10 French tertiary centres from 2013

68 en approached as a system of interactions of biological agents at different scales.

69 Concern regarding the use of biological agents--bacteria, viruses, or toxins--as tool

70 oday are complacent about the possibility of biological agents being intentionally used to cause wide

71 2004) for articles relating to bioterrorism, biological agents, biological warfare, hospital prepared

72 idually targeted therapies such as the newer biological agents, but how successful this approach will

73 onventional therapy is commonly scaled up to biological agents, but surgery can also offer excellent

74 n be protected against potentially hazardous biological agents by using engineering controls, good la

75 volumes, the cell microenvironment and other biological agents can be bioengineered; interactions bet

76 ention has been paid to scenarios in which a biological agent capable of person-to-person transmissio

77 All biological agents currently used for reducing TNFalpha a

78 able instruments for environmental analysis, biological agent detection, or diagnostics.

79 nostics, environmental testing and defensive biological agent detection.

80 ination procedures, the role of chemical and biological agent detectors, and potential environmental

81 t with regard to swallowed topical steroids, biological agents, dietary approaches, and novel molecul

82 muscarinic antagonists (eg, tiotropium), and biological agents directed against proteins involved in

83 Biological agents directed against the interleukin-13 pa

84 een reported in humans treated with anti-TNF biological agents, disparate rates of disease have been

85 The significant threat posed by biological agents (e.g. anthrax, tetanus, botulinum, and

86 ulin E and tumour necrosis factor alpha with biological agents, emphasise the need for careful phenot

87 cacy of a combination of methotrexate with a biological agent, especially a tumor-necrosis-factor blo

88 ation proposes methodologies for recovery of biological agent followed by an off-site unambiguous det

89 ur necrosis factor inhibitors were the first biological agents, followed by abatacept, rituximab, and

90 in the process of developing or acquiring a biological agent for use as a weapon.

91 Weaponization of biological agents for aerosol dispersal is difficult and

92 ocesses have led to the development of novel biological agents for the treatment of chronic inflammat

93 The development of biological agents for the treatment of solid tumours is

94 Introduction of biological agents for the treatment of the chronic infla

95 form of therapy for many patients, an era of biological agents for therapy in inflammatory bowel dise

96 Accidental release of biological agents from a bioweapon facility may contamin

97 The release of biological agents from conventional porous scaffolds is

98 For more than a decade, a biological agent has been suspected to cause free-branch

99 Deliberate contamination of food with biological agents has already been perpetrated in the US

100 elopment related to decontamination for this biological agent have increased substantially.

101 Biological agents have been used as instruments of warfa

102 Biological agents have dramatically improved treatment o

103 were rated high risk of bias showed that all biological agents have greater clinical efficacy than pl

104 he site of exposure, diseases resulting from biological agents have incubation periods of days.

105 en review current understanding of how these biological agents impact soil structure.

106 uld be carefully assessed when investigating biological agents in combination and should never be don

107 The integration of these new biological agents in combination with chemotherapy, in o

108 Our data suggest that the use of biological agents in IBD is safe.

109 Mechanisms causing non-response to biological agents in IBD remain to be fully understood.

110 gation tool as an identification paradigm of biological agents in interaction with bio-spesific compo

111 ty of cells or the transport of chemical and biological agents in living organisms.

112 es provide new tools to manipulate cells and biological agents in micro/nano-liter volumes.

113 ficacy of novel immunologic approaches using biological agents in patients with AD is available for t

114 These two fungal species were used as biological agents in Poland to control Melolontha melolo

115 Viruses are the most common biological agents in the sea, typically numbering ten bi

116 The role of biological agents in the treatment of this common, yet c

117 MSCs may serve as a platform for delivery of biological agents in tumors.

118 body temperatures in vitro but are effective biological agents in vivo.

119 s including X-ray contrast media (20.3%) and biological agents including human blood preparations (20

120 of intensity modulated radiation therapy and biological agents into CRT treatment approaches may redu

121 ell cancer, particularly the introduction of biological agents into treatment paradigms, and some of

122 olved in a plethora of cellular responses to biological agents involving activation of adenylyl cycla

123 products (SMNPs) in the discovery of active biological agents is discussed.

124 bel-free and direct detection of aerosolized biological agents is presented here.

125 ovocation test (DPT) with antineoplastic and biological agents is scarce.

126 care and with technological breakthroughs in biological agents, is giving new hope to the problem of

127 advantages over the conventional chemical or biological agents; it is free from cold chain storage, h

128 Published work suggests that biological agents, like traditional treatments, have the

129 ed mesenchymal stem cells (MSCs) can produce biological agents locally at tumor sites.

130 invisible, silent, odorless, and tasteless, biological agents may be used as an ultimate weapon-easy

131 der the importance of two neutrophil-derived biological agents: neutrophil extracellular traps and ec

132 ds, radio contrast media, chemotherapeutics, biological agents, nonsteroidal anti-inflammatory drugs,

133 molecular biology and the emergence of novel biological agents now offer the possibility of improved

134 Viruses are key biological agents of prokaryotic mortality in the world

135 Biological agents offer good control of rheumatoid arthr

136 olled by a magnetic field to deliver various biological agents on demand.

137 imes, hoaxes, or the accidental release of a biological agent or toxin for attribution purposes.

138 administration of molecular targeted drugs (biological agents or oral Janus kinase[JAK]inhibitors) m

139 Immunotherapy with biological agents or small molecules is revolutionising

140 , showcasing the effective "activation" of a biological agent otherwise inactive within the investiga

141 However, the incremental benefit of these biological agents over less expensive standard wound car

142 e a difference in the need for initiation of biological agents (P = 0.43) during 2 y of follow-up.

143 n more than 100 DPTs with antineoplastic and biological agents (paclitaxel, oxaliplatin, rituximab, i

144 its of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone

145 ildren and adults exposed to more than eight biological agents present in the home were at reduced ri

146 Encapsulated chemical and biological agents remarkably stimulate the synthesis of

147 Bats are also major hosts for biological agents responsible for zoonoses, such as coro

148 Among 9 RCTs evaluating biological agents, several trials reported benefits with

149 The addition of newer biological agents (strategy C) significantly decreased t

150 ctor-beta-directed therapies and other novel biological agents such as hyperimmune caprine serum are

151 Further trials are needed for biological agents such as infliximab, rituximab and intr

152 uding topical intranasal corticosteroids and biological agents, such as anti-IL-5 and anti-IgE mAb, a

153 ved to be less specific than perturbation by biological agents, such as antibody and small inference

154 Finally, we show that biological agents, such as oxidized 1-palmitoyl-2-arachi

155 Recent advances in the use of biological agents, such as rituximab, have also allowed

156 Clinical investigations of novel drugs and biological agents targeting mechanisms involving CD4 typ

157 ed studies confirm that the long-term use of biological agents targeting TNF-alpha in therapy for rhe

158 Biological agents that block key T-cell costimulatory si

159 Biological agents that block T-cell costimulatory pathwa

160 n be achieved in up to 50% of patients using biological agents that inhibit tumor necrosis factor (TN

161 We investigated biological agents that might enable this.

162 eness were primary reasons for discontinuing biological agents, the inability to obtain adequate insu

163 t of rheumatoid arthritis with the advent of biological agents, the mechanisms that drive cytokine pr

164 and the external environment and chemical or biological agents therein is the olfactory epithelium (O

165 protein, lysozyme (Lys), was selected as the biological agent to be immobilized.

166 potential inhibitors of the binding of such biological agents to cell membranes has increased.

167 icrobes and are therefore being developed as biological agents to control plant diseases.

168 edge of patient phenotypes and endotypes and biological agents to target specific classes of asthma e

169 The release of drugs or biological agents to the wound site can likewise be modu

170 Biological agents to treat pain (anti-calcitonin gene-re

171 e useful for preexposure prophylaxis against biological agents used as weapons of terror, such as Bac

172 l factors affecting AD development and novel biological agents used in the treatment of AD.

173 s the pathomechanism of adverse reactions to biological agents used to treat skin conditions and appl

174 few efforts in defining a role for the newer biological agents useful in rheumatoid arthritis and oth

175 or identifying the presence of spore-forming biological agents using 2D MS/MS as a rapid profiling sc

176 lapse rate at 6 months after introduction of biological agents was 13% (95% CI = 0.009-0.16).

177 The acrylamide mitigation potential of these biological agents was found to depend on factors includi

178 No adjuvant therapy with antiviral or biological agents was used.

179 0 bombs and 25 ballistic missiles laden with biological agents were deployed by the time Operation De

180 Biological agents were found to alter the psychopatholog

181 Diagnostic and biological agents were the most frequent causes of AN.

182 Biological agents were used in 45 episodes, the most com

183 suppressive drug, and in most cases to other biological agents, were studied.

184 re assigned to two treatment groups, i.e., a biological agent (which also included tofacitinib) or co

185 motherapy, oral agents, and newer injectable biological agents, which have revolutionised the managem

186 uency shifts indicated presence of the model biological agent with limit of detection of 1.45 x 10(4)

187 C patients continued treatment with the same biological agent with the addition of steroids, immunomo

188 The combination of probiotics, vitamins, and biological agents with AIT is highlighting current advan

189 This study provides comparative data on two biological agents with different mechanisms of action, w